BioXcel Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $98 | $120 | $168 | $366 |
Gross Profit | 12 | 13 | 154 | -466 |
EBITDA | -26,463 | -14,890 | -3,185 | -6,750 |
EBIT | -26,538 | -14,965 | -3,261 | -6,827 |
Net Income | -30,911 | -19,187 | -7,254 | -10,859 |
Net Change In Cash | 98 | 120 | 168 | 366 |
Free Cash Flow | -18,787 | -12,575 | -12,043 | -14,809 |
Cash | 37,320 | 17,435 | 31,013 | 29,854 |
Basic Shares | 14,196 | 7,843 | 4,834 | 3,039 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $2,266 | $1,380 | $375 | $0 |
Gross Profit | 123 | 120 | 355 | -297 |
EBITDA | -44,161 | -165,421 | -157,217 | -106,638 |
EBIT | -44,470 | -165,739 | -157,544 | -106,935 |
Net Income | -59,599 | -179,053 | -165,757 | -106,630 |
Net Change In Cash | 2,266 | 1,380 | 375 | 0 |
Cost of Revenue | -39,243 | 19,849 | ||
Free Cash Flow | -72,027 | -155,026 | -135,480 | -82,598 |
Cash | 29,854 | 65,221 | 193,725 | 232,968 |
Basic Shares | 2,535 | 1,820 | 1,750 | 1,648 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$2.18 |
2025-06-30 | -$2.45 |
2025-03-31 | -$1.50 |
2024-12-31 | -$3.56 |
